Immix Biopharma
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 17
- Market Cap
- $59.8M
- Website
- http://www.immixbio.com
- Introduction
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: IMX-110 combined with Tislelizumab
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Immix Biopharma, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05840835
- Locations
- 🇧🇷
Instituto do Cancer do Estado de São Paulo (ICESP), São Paulo, Sao Paulo, Brazil
🇧🇷CIP Centro Integrado de Pesquisa / Hospital de Base / Fundação Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, Brazil
News
Immix Biopharma's NXC-201 CAR-T Shows Promise in Relapsed/Refractory AL Amyloidosis
Immix Biopharma's NXC-201 demonstrates a 75% complete response rate in relapsed/refractory AL Amyloidosis patients, offering hope where no FDA-approved drugs exist.
Immix Biopharma's NXC-201 Advances to Expansion Cohort in US AL Amyloidosis Trial
Immix Biopharma's NXC-201, a CAR-T therapy for relapsed/refractory AL amyloidosis, has advanced to the expansion cohort in the NEXICART-2 trial.
Gene and Cell Therapies Show Promise in Treating Various Cardiac Diseases
Rocket Pharmaceuticals completed enrollment in a Phase 2 trial of RP-A501 gene therapy for Danon disease, targeting LAMP2 expression and left ventricular mass reduction.
Immix Biopharma's NXC-201 Shows Promise in AL Amyloidosis Treatment
Immix Biopharma's stock hits a 52-week low amidst market challenges, reflecting investor concerns about the company's financial performance.
Immix Biopharma Expands NXC-201 Clinical Trial Sites for AL Amyloidosis
Immix Biopharma broadens its NEXICART-2 trial for relapsed/refractory AL Amyloidosis by incorporating new clinical sites, enhancing patient accessibility.
Immix Biopharma's NXC-201 Shows Promise as Outpatient CAR-T Therapy in Amyloidosis and Multiple Myeloma
Immix Biopharma's NXC-201 has been administered to a significant number of patients with relapsed/refractory AL amyloidosis and multiple myeloma, showing potential in these challenging conditions.
Immix Biopharma's NXC-201 Receives EU Orphan Drug Designation for Multiple Myeloma
• Immix Biopharma's NXC-201 has been granted Orphan Drug Designation by the European Commission for treating multiple myeloma, a rare and life-threatening condition. • The designation provides NXC-201 with 10 years of market exclusivity in the EU upon approval, along with access to centralized authorization procedures. • This regulatory milestone underscores NXC-201's potential clinical impact, particularly for frail relapsed/refractory multiple myeloma patients with limited treatment options. • NXC-201 is currently being evaluated in the NEXICART-1 clinical trial, showing a favorable tolerability profile and potential for 'Single Day CRS'.
Immix Biopharma's Nexcella to Initiate US Dosing of NXC-201 CAR-T Therapy for AL Amyloidosis
Nexcella, a subsidiary of Immix Biopharma, is set to begin dosing patients in the U.S. with NXC-201 for relapsed/refractory AL Amyloidosis in mid-2024.
Immix Biopharma's NXC-201 CAR-T Therapy Shows Promise in AL Amyloidosis and Multiple Myeloma
Immix Biopharma's NXC-201, a BCMA-targeted CAR-T cell therapy, demonstrated a 100% overall response rate in relapsed/refractory AL amyloidosis patients in Phase 1/2a trials.
Immix Biopharma Completes Engineering Batch of NXC-201 CAR-T Therapy for U.S. Clinical Trial Expansion
Immix Biopharma successfully completed its third engineering batch of NXC-201, a BCMA-targeted CAR-T cell therapy, at its U.S. manufacturing site.